Cargando…
Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?
INTRODUCTION: Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476072/ http://dx.doi.org/10.1192/j.eurpsy.2021.1114 |
_version_ | 1784790058641915904 |
---|---|
author | Descalço, N. Medeiros, A.B. Santos, C. Fernandes Borges, G. |
author_facet | Descalço, N. Medeiros, A.B. Santos, C. Fernandes Borges, G. |
author_sort | Descalço, N. |
collection | PubMed |
description | INTRODUCTION: Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its interest in other psychiatric disorders such as obsessive-compulsive disorder (OCD) has grown. OBJECTIVES: To review the clinical evidence for the use of hallucinogens such as psilocybin in OCD. METHODS: Non-systematic review of literature found on PubMed/MEDLINE, Web of Science and Google Scholar, using the keywords “obsessive-compulsive disorder”, “psilocybin” and “hallucinogens”. Articles may include clinical trials, case report or case series. Articles found were admitted according to their relevance for the topic in review; only articles in English were included. Ongoing research trials on this topic were checked on ClinicalTrials.gov. RESULTS: So far, only one open-label non-randomized study directly assessed the effects of psilocybin on OCD patients that found acute reductions of obsessive-compulsive symptoms. Case reports of patients improving with off-label use of psilocybin are reported. There are two ongoing phase I research trials, aiming to explore the effect of the substance on symptomatology, hypothesizing that psilocybin will normalize cerebral connectivity and thus correlate with clinical improvement. CONCLUSIONS: More research to establish the usefulness of psilocybin in OCD patients is needed; the collected data is encouraging are there may be a role for its use on this disorder. |
format | Online Article Text |
id | pubmed-9476072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94760722022-09-29 Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? Descalço, N. Medeiros, A.B. Santos, C. Fernandes Borges, G. Eur Psychiatry Abstract INTRODUCTION: Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its interest in other psychiatric disorders such as obsessive-compulsive disorder (OCD) has grown. OBJECTIVES: To review the clinical evidence for the use of hallucinogens such as psilocybin in OCD. METHODS: Non-systematic review of literature found on PubMed/MEDLINE, Web of Science and Google Scholar, using the keywords “obsessive-compulsive disorder”, “psilocybin” and “hallucinogens”. Articles may include clinical trials, case report or case series. Articles found were admitted according to their relevance for the topic in review; only articles in English were included. Ongoing research trials on this topic were checked on ClinicalTrials.gov. RESULTS: So far, only one open-label non-randomized study directly assessed the effects of psilocybin on OCD patients that found acute reductions of obsessive-compulsive symptoms. Case reports of patients improving with off-label use of psilocybin are reported. There are two ongoing phase I research trials, aiming to explore the effect of the substance on symptomatology, hypothesizing that psilocybin will normalize cerebral connectivity and thus correlate with clinical improvement. CONCLUSIONS: More research to establish the usefulness of psilocybin in OCD patients is needed; the collected data is encouraging are there may be a role for its use on this disorder. Cambridge University Press 2021-08-13 /pmc/articles/PMC9476072/ http://dx.doi.org/10.1192/j.eurpsy.2021.1114 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Descalço, N. Medeiros, A.B. Santos, C. Fernandes Borges, G. Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? |
title | Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? |
title_full | Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? |
title_fullStr | Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? |
title_full_unstemmed | Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? |
title_short | Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? |
title_sort | psilocybin in the treatment of obsessive-compulsive disorder: what do we know so far? |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476072/ http://dx.doi.org/10.1192/j.eurpsy.2021.1114 |
work_keys_str_mv | AT descalcon psilocybininthetreatmentofobsessivecompulsivedisorderwhatdoweknowsofar AT medeirosab psilocybininthetreatmentofobsessivecompulsivedisorderwhatdoweknowsofar AT santoscfernandes psilocybininthetreatmentofobsessivecompulsivedisorderwhatdoweknowsofar AT borgesg psilocybininthetreatmentofobsessivecompulsivedisorderwhatdoweknowsofar |